<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05109884</url>
  </required_header>
  <id_info>
    <org_study_id>PC_LBI:AD_V3</org_study_id>
    <nct_id>NCT05109884</nct_id>
  </id_info>
  <brief_title>Comparison of PET Imaging Patterns With PSMA and AR Expression in Prostate Cancer and Bladder Cancer</brief_title>
  <official_title>Comparison of PET Imaging Patterns With Prostate-specific Membrane Antigen and Androgen Specific Receptor Expression Patterns in Prostate Cancer and Bladder Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients suffering either from newly diagnosed very high risk locally advanced and/or&#xD;
      oligometastatic prostate cancer (cohort A), metastatic castration-resistant prostate cancer&#xD;
      (mCRPC, cohort B), newly diagnosed postate cancer with planned radical prostatectomy (cohort&#xD;
      C) or primary bladder cancer with planned radical cystectomy (cohort D) as identified by a&#xD;
      multidisciplinary team of specialists, will be included.&#xD;
&#xD;
      PET imaging patterns using PSMA- and FDHT PET scans will be correlated with prostate-specific&#xD;
      membrane antigen and androgen specific receptor expression patterns in prostate cancer and&#xD;
      bladder cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2020</start_date>
  <completion_date type="Anticipated">February 2024</completion_date>
  <primary_completion_date type="Anticipated">February 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation of PET imaging parameters with PSMA and AR expression levels</measure>
    <time_frame>through study completion, an average of 3 years</time_frame>
    <description>To correlate PET imaging parameters with prostate-specific membrane antigen (PSMA), and androgen specific receptor expression levels in tissue biopsy samples using immuno-histochemical methods (IHC).</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>newly diagnosed very high risk locally advanced and/or oligometastatic prostate cancer</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>metastatic, castration resistant prostate cancer</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>newly diagnosed prostate cancer with planned radical prostatectomy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>primary bladder cancer with planned radical cystectomy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>PSMA PET Scan</intervention_name>
    <description>[68Ga]Ga-PSMAHBED-CC (Ga-PSMA) PET Scan</description>
    <arm_group_label>metastatic, castration resistant prostate cancer</arm_group_label>
    <arm_group_label>newly diagnosed prostate cancer with planned radical prostatectomy</arm_group_label>
    <arm_group_label>newly diagnosed very high risk locally advanced and/or oligometastatic prostate cancer</arm_group_label>
    <arm_group_label>primary bladder cancer with planned radical cystectomy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>FDHT PET Scan</intervention_name>
    <description>[18F]-fluoro-5α-dihydrotestosterone (18F-FDHT) PET Scan</description>
    <arm_group_label>metastatic, castration resistant prostate cancer</arm_group_label>
    <arm_group_label>newly diagnosed prostate cancer with planned radical prostatectomy</arm_group_label>
    <arm_group_label>newly diagnosed very high risk locally advanced and/or oligometastatic prostate cancer</arm_group_label>
    <arm_group_label>primary bladder cancer with planned radical cystectomy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Cohort A:&#xD;
&#xD;
          -  Age 18-75 years&#xD;
&#xD;
          -  Histologically or cytologically confirmed adenocarcinoma of the prostate with very&#xD;
             high risk for the development of metastases (defined as PSA ≥20 or Gleason Score ≥8 or&#xD;
             ≥cT3) and/or oligometastatic (T any, N positive, M any or T any, N any, M positive)&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status grade 0 or 1&#xD;
&#xD;
          -  Planned radical prostatectomy&#xD;
&#xD;
          -  ≤ 5 osseous metastasis&#xD;
&#xD;
          -  Signed and dated informed consent document indicating that the patient (or legally&#xD;
             acceptable representative) has been informed of all pertinent aspects of the trial&#xD;
             prior to study participation&#xD;
&#xD;
          -  Willingness and ability to comply with scheduled visits, treatment plans, laboratory&#xD;
             and radiographic assessments, and other study procedures&#xD;
&#xD;
        Cohort B - mCRPC:&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Histologically or cytologically confirmed prostate adenocarcinoma.&#xD;
&#xD;
          -  Presence of skeletal or nodal metastases according to one of the following criteria:&#xD;
&#xD;
          -  Confirmed pathological fracture related to the disease OR&#xD;
&#xD;
          -  Confirmation of distant bone and/or nodal metastases on CT or MRI scan or bone&#xD;
             scintigraphy.&#xD;
&#xD;
        OR&#xD;
&#xD;
          -  Positive pathology report of metastatic lesion.&#xD;
&#xD;
          -  Disease progression despite ADT as indicated by:&#xD;
&#xD;
          -  PSA increase that is ≥ 2 ng/mL and ≥ 25% above the minimum PSA as reached during ADT&#xD;
             or above the pre-treatment level, if no response was observed and which is confirmed&#xD;
             by a second value 1 or more weeks later.&#xD;
&#xD;
        OR&#xD;
&#xD;
          -  Progression of measurable lymph nodes (short axis ≥ 15 mm) or visceral lesion&#xD;
             measurable per RECIST OR&#xD;
&#xD;
          -  New metastatic lesions appearing on bone scan/imaging&#xD;
&#xD;
          -  Chemical or surgical castration&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance status 0-2.&#xD;
&#xD;
          -  Signed and dated informed consent document indicating that the patient (or legally&#xD;
             acceptable representative) has been informed of all pertinent aspects of the trial&#xD;
             prior to study participation&#xD;
&#xD;
          -  Willingness and ability to comply with scheduled visits, treatment plans, laboratory&#xD;
             and radiographic assessments, and other study procedures&#xD;
&#xD;
        Cohort C:&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Histologically or cytologically confirmed prostate adenocarcinoma.&#xD;
&#xD;
          -  Planned radical prostatectomy&#xD;
&#xD;
          -  Signed and dated informed consent document indicating that the patient (or legally&#xD;
             acceptable representative) has been informed of all pertinent aspects of the trial&#xD;
             prior to study participation&#xD;
&#xD;
          -  Willingness and ability to comply with scheduled visits, treatment plans, laboratory&#xD;
             and radiographic assessments, and other study procedures&#xD;
&#xD;
        Cohort D:&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Histologically or cytologically confirmed bladder cancer.&#xD;
&#xD;
          -  Planned radical cystectomy&#xD;
&#xD;
          -  Signed and dated informed consent document indicating that the patient (or legally&#xD;
             acceptable representative) has been informed of all pertinent aspects of the trial&#xD;
             prior to study participation&#xD;
&#xD;
          -  Willingness and ability to comply with scheduled visits, treatment plans, laboratory&#xD;
             and radiographic assessments, and other study procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Cohort A:&#xD;
&#xD;
          -  Tumour infiltration of the rectum or pelvic wall&#xD;
&#xD;
          -  Visceral metastasis&#xD;
&#xD;
          -  HIV positive&#xD;
&#xD;
          -  Any contraindication for surgery&#xD;
&#xD;
          -  Any other condition that, in the opinion of the Investigator, would impair the&#xD;
             patient's ability to comply with study procedures.&#xD;
&#xD;
          -  Any contraindication for performing a PET/MRI scan (if applicable)&#xD;
&#xD;
          -  Patient's not eligible for the size of the PET/MRI gantry&#xD;
&#xD;
        Cohort B - mCRPC:&#xD;
&#xD;
          -  HIV positive&#xD;
&#xD;
          -  Any contraindication for tissue biopsy (if tissue biopsy is planned)&#xD;
&#xD;
          -  Any contraindication for surgery (if surgery is planned)&#xD;
&#xD;
          -  Any other condition that, in the opinion of the Investigator, would impair the&#xD;
             patient's ability to comply with study procedures.&#xD;
&#xD;
          -  Any contraindication for performing a PET/MRI scan (if applicable)&#xD;
&#xD;
          -  Patient's not eligible for the size of the PET/MRI gantry&#xD;
&#xD;
        Cohort C:&#xD;
&#xD;
          -  Any contraindication for surgery&#xD;
&#xD;
          -  Any other condition that, in the opinion of the Investigator, would impair the&#xD;
             patient's ability to comply with study procedures.&#xD;
&#xD;
          -  Any contraindication for performing a PET/MRI scan (if applicable)&#xD;
&#xD;
          -  Patient's not eligible for the size of the PET/MRI gantry&#xD;
&#xD;
        Cohort D:&#xD;
&#xD;
          -  Any contraindication for surgery&#xD;
&#xD;
          -  Any other condition that, in the opinion of the Investigator, would impair the&#xD;
             patient's ability to comply with study procedures.&#xD;
&#xD;
          -  Any contraindication for performing a PET/MRI scan (if applicable)&#xD;
&#xD;
          -  Patient's not eligible for the size of the PET/MRI gantry&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Markus Zeitlinger, MD</last_name>
      <phone>004314040029810</phone>
      <email>markus.zeitlinger@meduniwien.ac.at</email>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 28, 2021</study_first_submitted>
  <study_first_submitted_qc>October 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2021</study_first_posted>
  <last_update_submitted>October 25, 2021</last_update_submitted>
  <last_update_submitted_qc>October 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Markus Zeitlinger</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

